A Pilot Study of the Impact of a Single Dose of Zoledronic Acid on Biomarkers in Breast Cancer
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Ductal carcinoma; Early breast cancer
- Focus Biomarker; Pharmacodynamics
- 20 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 18 Oct 2019 Planned End Date changed from 1 Apr 2019 to 1 Mar 2020.
- 01 Jun 2018 Planned End Date changed from 1 May 2018 to 1 Apr 2019.